The NeoTYPE Other Solid Tumor Profile analyzes 30 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.
- NGS (24 genes + 2 biomarkers): AKT1, BRAF, EGFR, FGFR1, FGFR2, FGFR3, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
- FISH (2 FISH): MET, PTEN (tech-only available)
- IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
The NeoTYPE Other Solid Tumor Profile characterizes primary or metastatic tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. This test can be used for tumors arising from various tissues including liver, pancreas, prostate, kidney, head and neck, or other tumors that do not match any subtypes of the 13 other tumor-specific NeoTYPE Profiles. These other profiles are available for specific tumors including brain, breast, colorectal, lung, thyroid, and others; please see separate listings for descriptions. The NeoTYPE Other Solid Tumor Profile is recommended for patients with resistant disease to explore options in clinical trials. This test is not for determining a tumor's tissue of origin.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.